May. 13 at 4:33 AM
$CVM Now we’re getting exactly the scenario I hoped CVM would avoid: a capital raise at a miserable price — and then, one or two weeks later, the SFDA approval drops. But this is Saudi Arabia. If Vision 2030 decides Dallah was the wrong partner and Amarox is the right one, then that’s simply how it goes.
But hey — it’s 14 million shares, plus maybe another 2 million at 40 USD once approval hits. Who cares.
